
Us2.ai
Founded Year
2017Stage
Incubator/Accelerator - II | AliveTotal Raised
$19.28MAbout Us2.ai
Us2.ai operates as an online healthcare technology platform. It provides automated echo reports with disease detection. It uses a heart risk detection tool to improve patient outcomes and expand healthcare access. It was formerly known as eko.ai. The company was founded in 2017 and is based in Singapore.
Loading...
Us2.ai's Product Videos


ESPs containing Us2.ai
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The radiology AI — cardiac ultrasound analytics market utilizes artificial intelligence to automate and improve the accuracy of cardiovascular disease diagnosis through ultrasound imaging. This technology eliminates the subjectivity and variability of manual analysis, allowing clinicians with all levels of experience to identify clinical abnormalities that are difficult to find visually. The algor…
Us2.ai named as Leader among 6 other companies, including Aidoc, Clarius Mobile Health, and Ultromics.
Us2.ai's Products & Differentiators
Us2.ai
AI software automating echocardiography analysis, interpretation and disease prediction
Loading...
Expert Collections containing Us2.ai
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Us2.ai is included in 2 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,987 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Us2.ai Patents
Us2.ai has filed 6 patents.
The 3 most popular patent topics include:
- cardiology
- medical imaging
- medical ultrasonography

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
11/9/2020 | 9/20/2022 | Medical ultrasonography, Medical imaging, Cardiology, Heart diseases, Remote desktop | Grant |
Application Date | 11/9/2020 |
---|---|
Grant Date | 9/20/2022 |
Title | |
Related Topics | Medical ultrasonography, Medical imaging, Cardiology, Heart diseases, Remote desktop |
Status | Grant |
Latest Us2.ai News
Sep 14, 2023
Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software Partnership will co-develop and commercialise AI tools for echocardiography to enable earlier detection, improved diagnosis and more efficient monitoring of heart failure Us2.ai uses machine learning to automate the fight against heart disease. (Credit: Pexels from Pixabay) Us2.ai, a Singapore-based MedTech firm, has partnered with Duke University to co-develop and commercialize AI tools for echocardiography, to enable earlier detection, improved diagnosis and more efficient management of heart disease. In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions. These include the syndrome of heart failure with a reduced or preserved left ventricular ejection fraction, cardiomyopathy, ischemia, acute myocardial infarction, valvular heart disease and/or pulmonary hypertension etc. Even at the most well-resourced setting, the process of acquiring, measuring, and analyzing the images is time-consuming and labor-intensive, making the routine echocardiography application unsustainable. Ground-breaking machine learning technology from Us2.ai utilises rigorously tested artificial intelligence (AI) algorithms to reduce the time to process and interpret echocardiograms from 30 minutes to under 2 minutes, with zero clicks, zero variability and with an accuracy comparable to expert clinicians1. “The presence of AI in cardiology is growing by day, from risk score generation to screening to management. Advances in deep learning have made automated analysis of medical images possible,” said Dr. Manesh Patel, Chief of Cardiology and Co-Director of the Heart Center at Duke University Health System. “We look forward to continuing our pioneering efforts to bring AI-automation to our echo labs and clinics.” Once an echocardiographer/sonographer acquires the necessary images for a study, the FDA and CE cleared Us2 software automatically performs a quality check while simultaneously classifying, annotating and analyzing all the heart chambers, using both 2D and Doppler views to create a full echo report with specific cardiac diagnoses. “This partnership accelerates our mission to automate the fight against heart disease,” said Dr. Carolyn Lam, Professor at Duke-NUS Graduate Medical School and co-founder of Us2.ai. “At Us2.ai, we continue to expand our collaborative network worldwide to further test and refine our innovative technology in different clinical settings and health care systems. We are proud to partner with Duke University and strengthen our global ties in cardiovascular research which we hope ultimately will benefit patients worldwide.” Us2.ai software automated measurements include 2-dimensional (cardiac volumes, all 4 chambers of the heart), M-mode (e.g. tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements) and tissue Doppler. This covers the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography. Source: Company Press Release
Us2.ai Frequently Asked Questions (FAQ)
When was Us2.ai founded?
Us2.ai was founded in 2017.
Where is Us2.ai's headquarters?
Us2.ai's headquarters is located at 2 College Road, Singapore.
What is Us2.ai's latest funding round?
Us2.ai's latest funding round is Incubator/Accelerator - II.
How much did Us2.ai raise?
Us2.ai raised a total of $19.28M.
Who are the investors of Us2.ai?
Investors of Us2.ai include Edison Accelerator, Partech Partners, EDBI, Peak XV Partners, Heal Partners and 11 more.
Who are Us2.ai's competitors?
Competitors of Us2.ai include DiA Imaging Analysis and 4 more.
What products does Us2.ai offer?
Us2.ai's products include Us2.ai.
Who are Us2.ai's customers?
Customers of Us2.ai include Brigham and Womens' Hospital.
Loading...
Compare Us2.ai to Competitors

Ultromics provides an artificial intelligence (AI)-based echocardiography imaging analysis platform. The company provides software solutions such as the EchoGo product, which enhances the accuracy of the diagnosis of cardiovascular situations and provides reports for clinicians without any need for physical software on-site. The company was founded in 2017 and is based in Oxford, United Kingdom.
AISAP provides artificial intelligence (AI) powered diagnosis services. Its cloud-based platform provides a comprehensive real-time analysis of images and data from ultrasound studies. The company was founded in 2022 and is based in Ramat Gan, Israel.
Nerveblox provides an AI-based platform. The company's platform assists anesthesiologists in visually experiencing peripheral nerve blocks as a decision-support solution. The company's software captures images from ultrasonography devices and uses an AI algorithm to label the anatomical landmarks. It was founded in 2019 and is based in Ankara, Turkey.

Aidoc provides a care coordination platform. It offers a wide range of solutions such as real-time notifications for neuro care, automatic analysis of imaging to identify abnormalities, and more. It was founded in 2016 and is based in Tel Aviv, Israel.

Ultrasight develops an automated ultrasound solution that provides AI-based navigation, analysis, and diagnosis at the point of care. It allows healthcare professionals to perform cardiac ultrasounds in a variety of settings at the point of care including clinics, community hospitals, ambulances, and remote and rural areas. The company was founded in 2018 and is based in Ness Ziona, Israel.

EchoNous provides medical equipment services. It develops devices that help monitor and assess heart, lung, and abdominal assessments with the help of artificial intelligence and machine learning. The company was founded in 2016 and is based in Redmond, Washington.
Loading...